Table 3. Hematological indexes and tumor markers before and at 1 month after DEB-TACE.
| Items | Before DEB-TACE (n=25) | One month after DEB-TACE (n=25) | P |
|---|---|---|---|
| WBC (×109/L) | 6.7 (5.5–7.8) | 6.9 (6.0–9.0) | 0.095 |
| RBC (×1012/L) | 3.9 (3.7–4.2) | 3.6 (3.5–4.2) | 0.044 |
| ANC (%) | 66.9 (60.0–73.1) | 77.5 (72.3–87.2) | <0.001 |
| Hb (g/L) | 122.0 (112.0–132.0) | 117.0 (106.0–125.5) | 0.007 |
| PLT (×109/L) | 248.0 (181.0–317.0) | 208.0 (166.5–296.0) | 0.042 |
| CEA (ng/mL) | 3.2 (2.2–10.0) | 3.0 (1.6–12.2) | 0.502 |
| CA125 (U/mL) | 41.7 (14.8–201.1) | 83.4 (18.9–182.2) | 0.859 |
| NSE (U/mL) | 18.9 (15.2–35.2) | 13.4 (11.4–55.1) | 1.000 |
| SCCAg (ng/mL) | 1.2 (0.8–4.4) | 0.9 (0.5–7.5) | 0.753 |
| Cyfra21-1 (ng/mL) | 6.0 (3.9–12.2) | 5.7 (3.3–22.3) | 0.594 |
Data were presented as median (25th-75th quantiles). Comparisons were determined by Wilcoxon signed rank test. P<0.05 was considered significant. DEB-TACE, drug-eluting beads-transcatheter arterial chemoembolization; WBC, white blood cell; RBC, red blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelet; CEA, carcinoembryonic antigen; CA125, Carbohydrate antigen 125; NSE, 2-phospho-D-glycerate hydrolase; SCCAg, squamous cell carcinoma antigen; Cyfra21-1, cytokeratin 19 fragment.